Use this url to cite publication: https://hdl.handle.net/20.500.12512/21283
Options
Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer
Type of publication
Straipsnis Web of Science duomenų bazėje / Article in Web of Science database (S1a)
Author(s)
Brugger, Wolfram | Schwarzwald-Baar Klinikum, Academic Teaching Hospital, University of Freiburg, Villingen-Schwenningen, Germany |
Triller, Nadja | Clinic for Respiratory and Allergic Diseases, Golnik, Slovenia |
Blasinska-Morawiec, Maria | Copernicus Memorial Hospital, Lodz, Poland |
Curescu, Stefan | Clinical City Hospital, Timisoara, Romania |
Manikhas, Georgy Moiseevich | City Oncology Dispensary, St Petersburg, Russia |
Mazieres, Julien | Larrey Hospital, Toulouse, France |
Whittom, Renaud | Hôpital du Sacré-Coeur, Université de Montréal, Montréal, Quebec, Canada |
Ward, Carol | F. Hoffmann-La Roche, Basel, Switzerland |
Trunzer, Kerstin | F. Hoffmann-La Roche, Basel, Switzerland |
Mayne, Karen | Roche, Welwyn Garden City, United Kingdom |
Cappuzzo, Federico | Istituto Di Ricovero e Cura a Carattere Scientifico, Rozzano, Italy |
Title
Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer
Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, Cappuzzo F
Publisher (trusted)
American Society of Clinical Oncology |
Is Referenced by
CINAHL |
Neuroscience Citation Index |
Date Issued
Date Issued |
---|
2011-11-01 |
Extent
p. 4113-4120.
Is part of
Journal of clinical oncology. Alexandria : American Society of Clinical Oncology, 2011, vol. 29, no. 31.
Version
Originalus / Original
Field of Science
Abstract
Purpose. The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended progression-free survival (PFS) and overall survival in patients with advanced non–small-cell lung cancer (NSCLC) who had nonprogressive disease following first-line platinum-doublet chemotherapy. This study included prospective analysis of the prognostic and predictive value of several biomarkers. Patients and methods. Mandatory diagnostic tumor specimens were collected before initiating first-line chemotherapy and were tested for epidermal growth factor receptor (EGFR) protein expression by using immunohistochemistry (IHC), EGFR gene copy number by using fluorescent in situ hybridization (FISH), and EGFR and KRAS mutations by using DNA sequencing. An EGFR CA simple sequence repeat in intron 1 (CA-SSR1) polymorphism was evaluated in blood. Results. All 889 randomly assigned patients provided tumor samples. EGFR IHC, EGFR FISH, KRAS mutation, and EGFR CA-SSR1 repeat length status were not predictive for erlotinib efficacy. A profound predictive effect on PFS of erlotinib relative to placebo was observed in the EGFR mutation–positive subgroup (hazard ratio [HR], 0.10; P < .001). Significant PFS benefits were also observed with erlotinib in the wild-type EGFR subgroup (HR, 0.78; P = .0185). KRAS mutation status was a significant negative prognostic factor for PFS. Conclusion. This large prospective biomarker study found that patients with activating EGFR mutations derive the greatest PFS benefit from erlotinib maintenance therapy. No other biomarkers were predictive for outcomes with erlotinib, although the study was not powered for clinical outcomes in biomarker subgroups. EGFR IHC–positive KRAS mutations were prognostic for reduced PFS. [...].
Type of document
type::text::journal::journal article
ISSN (of the container)
0732-183X
WOS
000296605100014
Other Identifier(s)
(LSMU ALMA)990000768060107106
Coverage Spatial
Jungtinės Amerikos Valstijos / United States of America (US)
Language
Anglų / English (en)